Biomedical research continually pushes the frontier of technological invention and subsequently therapeutic intervention.  Aptly described as a revolution, the advances achieved during this golden age of biotechnology will result in the development of a number of breakthrough therapies.  In no field is this statement more accurate than in the field of musculoskeletal research.  Moving beyond the traditional biomechanical explanations and rudimentary treatments associated with disorders such as osteoarthritis, scientists have begun to unravel the molecular mechanisms tied to the cause of such diseases.

LAGeT, Inc., a privately held Rochester, NY-based biotechnology company founded in 2001, believes that the next step in the evolution of therapeutic intervention will take place on the genetic, or DNA, level in the form of gene therapy. As a result, the Company has positioned itself to capitalize on this opportunity by designing a proprietary UV light-based medical device, termed LAGT (Light Activated Gene Therapy), which promises to greatly expand the utility of one of the most promising gene therapy vectors currently under development.

LAGeT Musculoskeletal LLC, a subsidiary of LAGeT Inc. has developed a technology process using the LAGT Laser for articular and meniscal cartilage repair, ligament and tendon healing and enhanced spinal fusion.